Literature DB >> 7509369

Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector.

L Gao1, B Chain, C Sinclair, L Crawford, J Zhou, J Morris, X Zhu, H Stauss.   

Abstract

Immunization of mice with a recombinant vaccinia virus expressing the human papillomavirus type 16 (HPV-16) E6 gene elicits specific antibody, proliferative and cytotoxic T lymphocyte responses. T and B cell epitopes were mapped by using synthetic peptides. This study provides the background to future investigation aimed at developing prophylactic and therapeutic vaccines against HPV-16 infection and cervical cancer.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7509369     DOI： 10.1099/0022-1317-75-1-157

Source DB:  PubMed          Journal:  J Gen Virol        ISSN： 0022-1317            Impact factor:   3.891


  12 in total

1.  A synthetic chimeric peptide harboring human papillomavirus 16 cytotoxic T lymphocyte epitopes shows therapeutic potential in a murine model of cervical cancer.

Authors:  Chandresh Sharma; M A Khan; Teena Mohan; Jatin Shrinet; N Latha; Neeta Singh
Journal:  Immunol Res       Date:  2014-01       Impact factor: 2.829

2.  Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.

Authors:  D W Liu; Y P Tsao; J T Kung; Y A Ding; H K Sytwu; X Xiao; S L Chen
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity.

Authors:  W Shi; P Bu; J Liu; A Polack; S Fisher; L Qiao
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

4.  Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth.

Authors:  D W Liu; Y P Tsao; C H Hsieh; J T Hsieh; J T Kung; C L Chiang; S J Huang; S L Chen
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

5.  T-cell proliferative response to human papillomavirus type 16 peptides: relationship to cervical intraepithelial neoplasia.

Authors:  M Nakagawa; D P Stites; S Farhat; A Judd; A B Moscicki; A J Canchola; J F Hilton; J M Palefsky
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

6.  Diversifying selection in human papillomavirus type 16 lineages based on complete genome analyses.

Authors:  Zigui Chen; Masanori Terai; Leiping Fu; Rolando Herrero; Rob DeSalle; Robert D Burk
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

7.  Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice.

Authors:  Yi-Fang Chen; Chih-Wei Lin; Yeou-Ping Tsao; Show-Li Chen
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

Review 8.  Selective mechanisms utilized by persistent and oncogenic viruses to interfere with antigen processing and presentation.

Authors:  R Ehrlich
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

9.  Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas.

Authors:  R Selvakumar; L A Borenstein; Y L Lin; R Ahmed; F O Wettstein
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

10.  Preventive and Therapeutic Vaccines against Human Papillomaviruses Associated Cervical Cancers.

Authors:  Khadem Ghaebi Nayereh; Ghaeb Khadem
Journal:  Iran J Basic Med Sci       Date:  2012-01       Impact factor: 2.699
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.